A new study, the phase 3 IMpower150, demonstrated Genentech’s atezolizumab (Tecentriq) and innovator bevacizumab (Avastin) plus paclitaxel and carboplatin chemotherapy significantly reduced the risk of disease worsening or death in the treatment of advanced lung cancer.
A new study, the phase 3 IMpower150, demonstrated Genentech’s atezolizumab (Tecentriq) and innovator bevacizumab (Avastin) plus paclitaxel and carboplatin chemotherapy significantly reduced the risk of disease worsening or death in the treatment of advanced lung cancer.
Genetech announced on November 20, 2017 that the study met its co-primary endpoint of progression-free survival (PFS) and showed that the combination of the 2 antibodies plus placlitaxel and carboplatin chemotherapy reduced the risk of disease worsening or death when compared with bevacizumab plus chemotherapy in the initial treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC).
Though initial observations are encouraging, these data are not fully mature and the next overall survival analysis is expected to take place in the first half of 2018. Safety for atezolizumab and bevacizumab appeared consistent with the safety profile of the individual medicines. No new safety signals were identified with the combination of the drugs.
“We are extremely encouraged by these results and will submit these data to health authorities globally with the goal of bringing a potential new standard of care for the initial treatment of lung cancer,” said Sandra Horning, MD, CMO and head of global product development for Genentech. “In addition to first-line NSCLC, we are testing the ability of atezolizumab and bevacizumab to enhance the potential of the immune system to combat a broad range of other cancers,” said Horning.
This announcement comes as Genentech appears to differentiate its reference bevacizumab from Amgen’s newly approved but as-yet unlaunced bevacizumab biosimilar, ABP 215 (Mvasi), which is the first biosimilar bevacizumab approved in the US. Currently, Amgen is in litigation against Genentech for having allegedly infringed on 27 patents covering the reference bevacizumab. With this new study, Genentech may be seeking to add another indication to its approval to further protect its marketshare for the top-selling Avastin.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.